Trial Profile
A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 microg b.i.d.) as an Active Control.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2017
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 02 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Jun 2011 New trial record